Stock Rating Lowered via ValuEngine
Molecular Templates Inc logoValuEngine reduced shares of Molecular Templates (NASDAQ: MTEM) from a hold score to a promote score in a file issued on Thursday, August first, ValuEngine reports.
Several different equities analysts additionally currently commented on the stock. BidaskClub downgraded stocks of Molecular Templates from a preserve score to a promote rating in studies observed on Friday, July twenty-sixth. UBS Group assumed coverage on shares of Molecular Templates in a study document on Monday, April twenty-ninth. They set a purchase score and a $12.00 charge goal for the inventory. Finally, Zacks Investment Research reduced stocks of Molecular Templates from a purchase rating to a preserve rating in a research report on Wednesday, June 5. Three funding analysts rated the stock with a sell rating, and seven gave a buy score to the enterprise’s inventory. Molecular Templates presently has a consensus score of Hold and an average rate goal of $13.58.
NASDAQ: MTEM traded up $0.22 for midday buying and selling on Thursday, hitting $five.00. The business enterprise had a buying and selling quantity of 113,981 shares compared to its average of 100,702. The enterprise has a short ratio of 3. Eleven has a modern-day ratio of 3.11 and a debt-to-equity ratio of zero.15. The corporation has a marketplace capitalization of $193.55 million, a PE ratio of -four.90, and a beta of 2.77. The inventory’s fifty-day transferring average rate is $6.41, and its 2 hundred-day moving common speed is $6.48. Molecular Templates has a 52-week low of $3.19 and a 52-week high of $8.Seventy-seven.
Molecular Templates (NASDAQ: MTEM) closing posted its quarterly income effects on Monday, August twelfth. The biotechnology corporation mentioned ($zero.25) income consistent with the share for the area, missing the consensus estimate of ($zero.23) through ($0.02). The enterprise had sales of $5—forty-five million in the sector, compared to the consensus estimate of $6.00 million. Molecular Templates had a terrible return on equity of 27. Seventy-two % and a poor internet margin of 113.Eighty-five %. As a set, research analysts forecast that Molecular Templates will submit -0.Ninety-two earnings in line with a share for the current year.
Several hedge price range has recently made changes to their positions in MTEM. BlackRock Inc. grew its role in stocks of Molecular Templates through 26.Four in the course of the fourth region. BlackRock Inc. Now owns 743,893 of the biotechnology company’s stock worth $three 0.5,000 after acquiring a further 155,240 shares over the last part. Bank of New York Mellon Corp grew its role in Molecular Templates by 37.6% inside the 4th sector. Bank of New York Mellon Corp now owns 36,854 stocks of the biotechnology corporation’s inventory worth $149,000 after shopping for an additional 10,076 shares over the last sector.
Northern Trust Corp grew its position in Molecular Templates by 59.2% within the 4th sector. Northern Trust Corp now owns 165,677 of the biotechnology employer’s stock worth $669,000 after shopping for an extra sixty-one 616 stores over the last region. Geode Capital Management LLC grew its function in Molecular Templates with the aid of 78.1% within the 4th area. Geode Capital Management LLC now owns 134,069 stocks of the biotechnology company’s inventory worth $541,000 after shopping for a further 58,780 stores over the past zone. Finally, Fosun International Ltd. grew its function in Molecular Templates by 39.Three inside the 1st region.
Fosun International Ltd now owns 162,991 stocks of the biotechnology agency’s inventory worth $940,000 after shopping for an additional 45,968 stores over the last region. Hedge price range and other institutional investors personal 38.29% of the company’s stock. Molecular Templates, Inc., a clinical-stage oncology business enterprise, focuses on discovering and developing biological therapeutics for the treatment of most cancers and different diseases. The business enterprise typically creates a pipeline of engineered toxins in our bodies. Its lead drug candidate is MT-3724; this is in a Phase II clinical trial to remedy relapsed/refractory diffuse big B-cellular lymphoma and a Phase II scientific trial for treating non-Hodgkin’s lymphoma.